drugset / Trial / NCT00089804

Study of LJP 394 in Lupus Patients With History of Renal Disease

NCT00089804 ↗

Phase 3 Terminated 943 enrolled La Jolla Pharmaceutical Company
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.

Timeline

Start
2004-10
Primary completion
2009-02
Completion
2009-02

Outcome

Outcome not reported

Stopped: “Interim efficacy analysis indicated it would be futile to continue study.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abetimus Unknown 300 mg Intravenous
Comparator Abetimus Unknown 900 mg Intravenous